drugset / Trial / NCT05001373
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
Phase 1
Unknown
56 enrolled
International AIDS Vaccine Initiative
Emory University · collabFred Hutchinson Cancer Center · collabGeorge Washington University · collabModernaTX, Inc. · collabThe University of Texas Health Science Center at San Antonio · collab
RandomizedSequentialOpen-labelPrevention
Summary
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health
Timeline
- Start
- 2021-11-12
- Primary completion
- 2023-06-20
- Completion
- 2024-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Core-g28v2 60mer mRNA Vaccine | Messenger RNA (mRNA) | 100 ug | Intramuscular |
| Subject | eOD-GT8 60mer mRNA Vaccine | Messenger RNA (mRNA) | 100 ug | Intramuscular |